CADLMEDIUM SIGNALFINANCIAL10-K

CADL rebranded its lead product candidate from CAN-2409 to aglatimagene while experiencing substantially higher R&D expenses and a notable shift in liability composition.

The product rebranding suggests CADL is preparing for potential commercialization as it advances through pivotal Phase 3 trials, moving away from clinical development nomenclature toward a market-ready name. The substantial increase in R&D spending aligns with advancing clinical programs, though it's pressuring operating performance and cash burn rates.

Comparing 2026-03-12 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

CADL's financial position shows mixed signals with cash increasing modestly to $119.7M providing continued runway, but R&D expenses grew substantially reflecting advancing clinical programs. The company experienced a dramatic shift in liability structure with total liabilities increasing 81% while current liabilities dropped 76%, suggesting a move toward longer-term obligations. Operating losses expanded meaningfully while net income improved due to non-operating factors, and cash burn accelerated with operating cash flow declining to -$38.3M.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
+80.7%
$40.5M→$73.3M

Liabilities grew 80.7% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Liabilities
Balance Sheet
-76%
$37.5M→$9.0M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
+57.9%
$19.3M→$30.5M

R&D investment increased 57.9% — signals commitment to future product development, though near-term margin impact.

Operating Income
P&L
-44.6%
-$33.4M→-$48.3M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Operating Cash Flow
Cash Flow
-41.8%
-$27.0M→-$38.3M

Operating cash flow fell 41.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Net Income
P&L
+30.8%
-$55.2M→-$38.2M

Net income grew 30.8% — bottom-line growth signals improving overall business health.

Stockholders Equity
Balance Sheet
-21.7%
$66.3M→$51.9M

Equity decreased 21.7% — buybacks or losses reducing book value, monitor solvency ratios.

Total Assets
Balance Sheet
+17.2%
$106.9M→$125.2M

Asset base grew 17.2% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+16.9%
$103.8M→$121.4M

Current assets grew 16.9% — improving short-term liquidity or inventory/receivables build.

Cash & Equivalents
Balance Sheet
+16.6%
$102.7M→$119.7M

Cash grew 16.6% — improving liquidity position supports investment and shareholder returns.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-13
ADDED
Our business is dependent on the success of aglatimagene, linoserpaturev and any other product candidates that we advance into the clinic.
Local administration is designed to achieve these therapeutic effects while minimizing systemic exposure and associated toxicity.
Our most advanced product candidate, aglatimagene besadenovec (referred to herein as aglatimagene and previously as CAN-2409), is an off-the-shelf adenovirus product candidate, administered in conjunction with the prodrug valacyclovir, and has generated promising clinical activity across a range of solid tumor indications.
Aglatimagene is being studied in the following ongoing clinical trials: Prostate Cancer o A pivotal phase 3 randomized, double-blind, placebo-controlled clinical trial in the United States under a Special Protocol Assessment (SPA) with the U.S.
o The primary goal of curative treatment for localized prostate cancer is complete tumor eradication, as outlined by National Comprehensive Cancer Network (NCCN) guidelines.
+7 more — sign up free →
REMOVED
Our business is dependent on the success of CAN-2409, CAN-3110 and any other product candidates that we advance into the clinic.
Our biological multimodal immunotherapy approach utilizes intratumoral administration of genetically engineered viruses to induce tumor cell death and elicit a systemic anti-tumor response.
Local delivery enables us to achieve these effects while aiming to minimize systemic toxicity.
Our most advanced product candidate, CAN-2409, is an off-the-shelf adenovirus product candidate which is administered in conjunction with the prodrug valacyclovir, that has generated promising clinical activity across a range of solid tumor indications.
CAN-2409 is currently being studied in the following ongoing clinical trials: Prostate Cancer o A pivotal phase 3 randomized, triple-blinded and placebo-controlled clinical trial in the United States under a Special Protocol Assessment (SPA), with the U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →